AbCellera Biologics Inc. (ABCL): Revenue
$75.13M
Year ended 2025-12-31
$66.17M
Trailing 12 months to 2026-06-30
-46.3%
3-year compound annual growth
-20.3%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $75.13M | +160.6% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $28.83M | -24.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $38.02M | -92.2% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $485.42M | +29.4% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $375.20M | +60.9% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $233.16M | n/m | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $11.61M | n/a | 2022-02-25, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $72.59M | +105.8% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $72.30M | +153.5% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $70.85M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $79.95M | +104.9% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $81.36M | +14.9% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $82.03M | -46.1% |
Compare ABCL, CTMX, BCYC, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗